Amit Singal, MD, discusses the current treatment landscape for patients with hepatocellular carcinoma and how the treatments differ among patients caught in early-stage versus late-stage at the 2019 International Liver Cancer Association Annual Conference.
Amit Singal, MD, medical director of the Liver Cancer Program at UT Southwestern Medical Center, discusses the current treatment landscape for patients with hepatocellular carcinoma (HCC) and how the treatments differ among patients diagnosed in the early stage versus late stage at the 2019 International Liver Cancer Association Annual Conference.
For patients with HCC where the disease is caught at an early stage, curative options are available, Singal says. These therapies include surgical resection of the liver, local ablation, and liver transplantation. These treatments can afford a 5-year survival in over 60% of patients.
However, Singal notes that patients with disease found at a more intermediate or advanced stage have different treatment options, including palliative therapies such as chemoembolization, radioembolization, radiation-based therapies, or systemic therapies, like tyrosine kinase inhibitors.
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More